ALLOPURINOL-INDUCED STEVENS–JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS: A CASE REPORT by CHHABRA, MANIK & GAUR, ANKIT
Vol 12, Issue 2, 2019
Online - 2455-3891 
Print - 0974-2441
ALLOPURINOL-INDUCED STEVENS–JOHNSON SYNDROME AND TOXIC EPIDERMAL 
NECROLYSIS: A CASE REPORT
MANIK CHHABRA*, ANKIT GAUR
Department of Pharmacy Practice, Indo-Soviet Friendship College of Pharmacy, Moga, Punjab, India. Email: manikchhabra57@gmail.com
Received: 01 September 2018, Revised and Accepted: 02 November 2018
ABSTRACT
Allopurinol is used for the treatment of gout and related conditions; it is associated with various adverse drug reactions (ADRs) such as Stevens–
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A 50-year-old female was presented to the emergency ward with chief complaints of 
reddish pinpoint lesions over the back, chest, abdomen, and lower limb-upper limb for the past 6 days. She was diagnosed with SJS. On medication 
interview, it was revealed that she was on allopurinol therapy, which she took 5 days back as a self-medication. The World Health Organization - Uppsala 
Monitoring Centre (WHO) scale was used to access the causality assessment, ADR was found to be probable. The drug was withdrawn from the 
therapeutic regimen of the patient. The patient was discharged after 25 days from the hospital. Allopurinol has the strongest association with SJS with 
TEN. There should be a screening of HLA-B 5801 antigens before commencing the allopurinol therapy to the patients.
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INTRODUCTION
Whenever a drug therapy is initiated, risk is taken beside the therapeutic 
effects and that risk may result in adverse drug reactions (ADRs). ADRs 
are a sixth leading cause of death worldwide [1]. Risk of ADR with 
marketed pharmaceutical formulation is assessed through voluntary 
reporting of ADR by various health-care professionals who further 
decides the marketing of that particular pharmaceutical formulation [2]. 
The most serious ADRs are the mucocutaneous ADRs through their rate 
of occurrence is relatively low but are potentially fatal and endanger 
patient’s life [3]. Most common culprits of mucocutaneous ADR are 
antiepileptic drugs, antimicrobial drugs, sulfa drugs, nonsteroidal anti-
inflammatory drugs (NSAIDs), and antirheumatic drugs [4]. Stevens–
Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) are 
categorized under cutaneous ADRs. SJS and TEN are rare, responsible 
for around 1 or 2/100,000 cases annually and are potentially fatal 
due to which they are considered as a medical emergency. In the year 
1922, SJS was described for the 1st time in two young boys [5]. As per 
the criteria laid by international group of dermatologist, SJS is an acute 
mucocutaneous adverse reaction, characterized by erosion or bullae 
with erythematous base. Reaction covering ≥20% of body surface area 
with three distinct involvement of anatomical areas, peeling of area 
of skin larger than 3 cm, frequent involvement of mucous membrane 
with character of appearance of tenderness within 48 h of onset of 
rash, drug-induced basal necrosis TEN, and specimen compatible 
with SJS [6]. This definition excludes staphylococcal skin syndrome 
and appearance of the lesion that has been exposed to sunlight. Both 
SJS and TEN relatively affect 1 or 2/1000,000 people every year [7]. 
Habitually patients diagnosed with SJS-TEN complain of burning rash 
with symmetric origin on the face and upper part of the torso. The rash 
starts to begin as macules and on progression, it develops into papules, 
vesicles bullae, and urticarial plaques. Later on, signs of mucosal 
involvement include erythema, edema, sloughing, blistering, ulceration, 
and necrosis [8].
CASE REPORT
A 50-year-old female presented to the emergency department with 
reddish pinpoint lesions over the back, chest, abdomen, and lower 
limb-upper limb for the past 6 days was slowly progressing and had a 
complaint of gradually increasing oral ulceration for the past 5 days. 
History dates back to 5 to 6 days back, she took allopurinol for joint 
pain as a self-medication after 2 days of administration of allopurinol, 
she developed erythematous maculopapular rashes all over the 
body which started over upper limbs and gradually involved chest, 
abdomen, back, and lower limb gradually, she developed ulceration 
over mouth and followed by blistering of the lips. She also developed 
redness of eye along with photophobia and mucopurulent discharge 
from both eyes. Nikolsky’s sign appeared to be positive. The patient 
had a history of epistaxis and burning micturition; the patient case of 
hypothyroidism previously and was on irregular medication for the 
past 3 months. On examination, the patient was semiconscious and 
her blood pressure was 140/90 mmHg, respiratory rate was 18 per 
min, pulse rate was 78 beats per minute, and oral temperature was 
97.8°F on day admission, but after 3 days, she turned febrile with 
high-grade fever, her oral temperature was 103°F which was relieved 
by administration of paracetamol. All the laboratories investigations 
were almost normal, her hemoglobin, mean corpuscular volume, 
mean corpuscular hemoglobin, and hematocrit were low-indicating 
megaloblastic anemia, urine examination was also normal, IgE and 
IgM antibodies were negative, random blood sugar was 165 mg/dL, 
RFT were quite normal, and total serum protein and albumin were 
normal. Her liver enzymes were elevated, serum glutamic oxaloacetic 
transaminase was found to be 75 IU/L, SGPT was 84 IU/L, and 25% of 
body surface was affected. Differential diagnosis like herpes simplex 
virus autoimmune disorders of skin like pemphigus vulgaris, fix drug 
eruptions, erythema multiforme were ruled out. The final diagnosis 
of SJS was made. The causality of ADR and allopurinol was accessed 
using the WHO causality scale and ADR was found to be probable. 
Details of the drug therapy administered to the patient are shown in 
Table 1.
The patient’s condition was improved and was discharged after 
25 days from the hospital. The patient was advised not to administer 
allopurinol in the future. Prediction of course of a disease was done 
with score TEN scale to predict the percentage of mortality rate with 
the risk factor associated with SJS-TEN. Score TEN is well described in 
Tables 2 and 3 [9].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.29448
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DISCUSSION
Long back in the year 1922, SJS was described for the 1st time as rare, 
unspecified epidermal eruptions characterized by pyrexia, swelling of 
buccal mucosa, and austere conjunctivitis by American pediatricians 
Albert Mason Stevens and Frank Chambliss Johnson in two young boys 
of age 7 and 8 years. Both these cases were misdiagnosed by primary 
physician as hemorrhagic measles [10]. The incidence of SJS is relatively 
very low. Multiple etiologies are involved in the pathophysiology of 
this syndrome. Various drugs such as NSAIDs, sulfonamides, and 
antiepileptic, including allopurinol, several infectious agents, and 
idiopathic reasons are responsible for the cause of SJS [11]. Their strong 
evidence of the association between HLA-B 5801 and occurrence of SJS-
TEN allopurinol induced [12]. The mortality rates are higher in younger 
and older age. There are various studies, suggesting that patients 
suffering from HIV are at higher risk of developing SJS and TEN. The 
terminology of SJS and TEN is assigned as if the 10% of the body surface 
is covered than the subject is having SJS similarly if 10–30% of body 
surface area than SJS and TEN overlaps and >30% is said to be TEN [13].
An approach to treatment is based on the symptoms and is 
supportive begins with cessation of the culprit drug responsible 
for its etiology [14]. Treatment was initiated with the management 
of airways, fluid electrolyte management, and wound care. For skin, 
lesions, or skin loss, patients are treated as burn patients with extra 
care and are shifted to burn care units. Paradesi et al. found that 
patients who were on etanercept therapy were more promising with 
the median healing time of 8.5 days [15]. There are studies, which are 
not favoring the use of corticosteroids, but still, these are used in the 
management of SJS TEN.
CONCLUSION
Allopurinol has the strongest association with SJS-TEN. Early diagnosis 
of SJS-TEN and initiation of therapy with the systemic corticosteroid 
and supportive medication proved to be useful in the management of 
the patients. An early approach is to withdraw the drug and initiation of 
supportive measures [16-21]. Better how there should be a screening 
of HLA-B 5801 before commencing the therapy of allopurinol to the 
patients.
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